摘要:
The present invention relates to a novel molecular marker for pancreatic cancer stem cells and pancreatic cancer, to a marker detection method, and to a screening method. The present invention is a marker discovered from the cell lines of pancreatic cancer, wherein the marker may detect pancreatic cancer, in particular early pancreatic cancer, through the detection of a pancreatic cancer stem cell marker. In addition, the marker of the present invention may enable an accurate diagnosis and prognosis analysis of pancreatic cancer.
摘要:
The present invention relates to a method for screening for a cancer treatment agent by contacting a test material with pancreatic adenocarcinoma upregulated factor (PAUF) and GLRX3, SNAPIN, or UBL4A, as a binding partner for PAUF, and then analyzing whether or not the test material inhibits the binding of the PAUF and GLRX3, SNAPIN, or UBL4A serving as a binding partner therefor, thereby determining that the test material is a cancer treatment agent if the binding is inhibited. The invention also relates to a pharmaceutical composition containing the test material as an active ingredient for inhibiting and treating cancer. The pharmaceutical composition of the present invention, which contains, as an active ingredient, an inhibitor for inhibiting PAUF from binding with a binding partner, effectively inhibits PAUF signaling related to the onset of cancer, thus enabling various kinds of cancer (especially pancreatic cancer) to be treated.
摘要:
The present invention relates to a method for screening for a cancer treatment agent by contacting a test material with pancreatic adenocarcinoma upregulated factor (PAUF) and GLRX3, SNAPIN, or UBL4A, as a binding partner for PAUF, and then analyzing whether or not the test material inhibits the binding of the PAUF and GLRX3, SNAPIN, or UBL4A serving as a binding partner therefor, thereby determining that the test material is a cancer treatment agent if the binding is inhibited. The invention also relates to a pharmaceutical composition containing the test material as an active ingredient for inhibiting and treating cancer. The pharmaceutical composition of the present invention, which contains, as an active ingredient, an inhibitor for inhibiting PAUF from binding with a binding partner, effectively inhibits PAUF signaling related to the onset of cancer, thus enabling various kinds of cancer (especially pancreatic cancer) to be treated.
摘要:
The invention relates generally to the changes in gene expression in human pancreatic adenocarcinoma. The invention relates specifically to a human gene family which is differentially expressed in cancerous pancreatic tissues compared to corresponding non-cancerous pancreatic tissues.
摘要:
The present invention relates to an apparatus for rejecting images in a receiver.The apparatus of the present invention relates to an apparatus for rejecting image signals in a receiver of a direct conversion structure and comprises a signal mismatch compensation unit configured to detect gain error and phase error between an In-phase (I) signal and a Quadrature (Q) signal received through the receiver, to reject image signals existing in the I and Q signals, and to output a result. The signal mismatch compensation unit detects the gain error and the phase error using an adaptive step method of reducing the step size of the gain error and the phase error step by step whenever the gain error and the phase error are converged.According to the present invention, high image rejection ratio is achieved and the adaptation time taken to obtain a high image rejection ratio is reduced simultaneously. Further, a bad influence of the DC offset on the image rejection ratio can be prevented by removing DC offset signals in a digital structure, accordingly, error can be accurately estimated.
摘要:
The invention relates generally to the changes in gene expression in human pancreatic adenocarcinoma. The invention relates specifically to a human gene family which is differentially expressed in cancerous pancreatic tissues compared to corresponding non-cancerous pancreatic tissues.
摘要:
The present invention relates to a novel molecular marker for pancreatic cancer stem cells and pancreatic cancer, to a marker detection method, and to a screening method. The present invention is a marker discovered from the cell lines of pancreatic cancer, wherein the marker may detect pancreatic cancer, in particular early pancreatic cancer, through the detection of a pancreatic cancer stem cell marker. In addition, the marker of the present invention may enable an accurate diagnosis and prognosis analysis of pancreatic cancer.
摘要:
The present invention relates to an apparatus for rejecting images in a receiver.The apparatus of the present invention relates to an apparatus for rejecting image signals in a receiver of a direct conversion structure and comprises a signal mismatch compensation unit configured to detect gain error and phase error between an In-phase (I) signal and a Quadrature (Q) signal received through the receiver, to reject image signals existing in the I and Q signals, and to output a result. The signal mismatch compensation unit detects the gain error and the phase error using an adaptive step method of reducing the step size of the gain error and the phase error step by step whenever the gain error and the phase error are converged.According to the present invention, high image rejection ratio is achieved and the adaptation time taken to obtain a high image rejection ratio is reduced simultaneously. Further, a bad influence of the DC offset on the image rejection ratio can be prevented by removing DC offset signals in a digital structure, accordingly, error can be accurately estimated.